J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
Metrics to compare | JBCH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJBCHPeersSector | |
---|---|---|---|---|
P/E Ratio | 51.5x | 42.2x | −0.6x | |
PEG Ratio | 1.73 | 0.69 | 0.00 | |
Price/Book | 10.3x | 6.5x | 2.6x | |
Price / LTM Sales | 8.4x | 5.5x | 3.2x | |
Upside (Analyst Target) | 12.9% | 3.0% | 48.9% | |
Fair Value Upside | Unlock | −13.8% | 7.2% | Unlock |